PanTheryx Advisors and Collaborators
Dr. Alan Greene, MD
Chief Pediatric Advisor and pediatrician in private practice
Founding President of the Board of the Society of Participatory Medicine (SPM)
Dr. Greene is a pediatrician in private practice, committed to giving extraordinary care to his patients. He has served as both President and Board Chair of SPM and Hi-Ethics (Health Internet Ethics).
Dr. Stephen Berman, MD
University of Colorado School of Medicine
Section Head, General Academic Pediatrics
Children’s Hospital of Colorado
Dr. Berman is former President of American Academy of Pediatrics (AAP) and is the Director of the Center for Global Health at the University of Colorado, Colorado School of Public Health.
Dr. Steven Gundry, MD
Cardiothoracic surgeon, former head of Cardiothoracic Surgery at Loma Linda University
Founder of The Center for Restorative Medicine
In his 40-year career, Dr. Gundry completed over 1,000 surgeries and patented life-saving medical technologies. He has also founded wellness centers, pursued international charitable services, and is a best-selling author on gut nutrition and the microbiome.
Dr. Simon Cutting, PhD
Professor, Molecular Microbiology
Royal Holloway University of London
Professor Simon M. Cutting is a bacterial geneticist with a PhD from Oxford University. After spending 7 years in the laboratory of Professor Richard Losick at Harvard University Biological Laboratories, he spent 3 years as an Assistant Professor at the University of Pennsylvania Medical School in Philadelphia. Dr. Cutting is Chairperson of the C. Difficile Foundation’s Research & Development Committee.
Dr. Gayatri Vedantam, PhD
Professor, Animal & Comparative Biomedical Sciences, Pathology
University of Arizona
Dr. Vedantum’s research is focused on elucidating the mechanisms behind C. difficile colonization at the molecular level, with a specific goal of targeting early bacterial establishment as a mechanism for disease prevention. Molecular biology, biochemistry, genomics and proteomics techniques as well as several in vivo models are employed for this research effort.
Dr. Rachel Gibson, PhD
Professor, Health and Medical Sciences Faculty Office
Inaugural Professor and Director of Allied Health
University of Adelaide, Australia
Dr. Gibson is the inaugural Professor and Director of Allied Health at the University of Adelaide. In addition, she is Co-Head of the Cancer Treatment Toxicities Group at the Adelaide Medical School. Dr. Gibson’s main research interest is supportive care in cancer. She works with a team of cross functional team of researchers in the study of toxic effects of chemotherapy on the gut microbiome of cancer patients.
Dr. Joanne Bowen, PhD
Associate Professor, Faculty of Health and Medical Sciences
Adelaide Medical School, University of Adelaide, Australia
Dr. Bowen’s research focuses on mechanisms and management of cancer therapy-related toxicities, with a special interest in gastrointestinal adverse effects. As co-head of the Cancer Treatment Toxicities Group, her current research focus on establishing new interventions for mitigation of gastrointestinal side effects that target interactions between the gut microbiome and immune system at the level of the mucosal barrier.
Dr. Paul Kelly, MD
Professor, Tropical Gastroenterology
Queen Mary, University of London
Dr. Kelly is currently a Professor of Tropical Gastroenterology at Bart & The London. He previously served as a reviewer in Tropical Gastroenterology from 2003-2013. Dr. Kelly has published over 120 research articles related to various aspects of gastroenterology in the tropics. His work includes several trials of treatment for cryptosporidiosis and nutritional approaches to environmental enteropathy.
Dr. Michael Riggs, PhD
Professor, School of Animal and Comparative Biomedical Sciences, College of Agriculture and Life Sciences
Joint Professor, Department of Pathology, College of Medicine
University of Arizona
Dr Riggs research program centers on the immunobiology of bovine and human cryptosporidiosis, a common diarrheal disease of humans and livestock worldwide caused by the parasitic protozoan parasites Cryptosporidium parvum and C. hominis. This focus includes characterizing protective immune responses; developing recombinant vaccines, and other new immunotherapeutic discoveries for cryptosporidiosis.